News OptiNose, Inc.

Equities

OPTN

US68404V1008

Real-time Estimate Cboe BZX Other stock markets 01:11:08 30/04/2024 am IST			5-day change	1st Jan Change
0.854 ^USD	-0.74%		-17.05%	-33.77%

25/04	OptiNose, Inc. Provides Revenue Guidance for the First Quarter of 2024	CI
25/04	Transcript : OptiNose, Inc. - Special Call

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OptiNose, Inc. Provides Revenue Guidance for the First Quarter of 2024	25/04	CI
Transcript : OptiNose, Inc. - Special Call	25/04
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million	25/04	AQ
OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025	25/04	CI
Optinose, Inc. Announces Preliminary XHANCE Net Product Revenue Results for the First Quarter Ended March 31, 2024	25/04	CI
Optinose to Present at the Needham Virtual Healthcare Conference	05/04	AQ
Lake Street Adjusts Price Target on OptiNose to $4 From $3, Maintains Buy Rating	18/03	MT
Sector Update: Health Care Stocks Steady Premarket Monday	18/03	MT
OptiNose Says US FDA Approves Xhance to Treat Chronic Rhinosinusitis	16/03	MT
Optinose Says FDA Approves Xhance to Treat Chronic Rhinosinusitis	16/03	DJ
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps	16/03	AQ
OptiNose, Inc. Announces U.S. Food and Drug Administration Approved XHANCE (Fluticasone Propionate) Nasal Spray for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps in Patients 18 Years of Age and Older	16/03	CI
Optinose, Inc. Provides Update on Hikma Manufacturing Agreement	15/03	CI
Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?	14/03	PR
HC Wainwright Initiates OptiNose With Buy Rating, $5 Price Target	11/03	MT
Transcript : OptiNose, Inc., Q4 2023 Earnings Call, Mar 07, 2024	07/03
OptiNose: Q4 Earnings Snapshot	07/03	AQ
Earnings Flash (OPTN) OPTINOSE Posts Q4 Revenue $19.9M	07/03	MT
OptiNose, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights	07/03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News OptiNose, Inc.

Equities

OPTN

US68404V1008

Summary

Filters